PDCD1LG2 and melanoma: Among melanoma tumors, the biomarkers PD-L1, PD-L2 and CTLA-4 and those of “Effector molecule” category, such as Expanded immune signature and T cell-inflamed GEP, were significantly associated with favorable outcomes (Figure 6A, Table S3b).